First‐in‐Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742, a Dual Antagonist of Toll‐like Receptors 7 and 8, in Healthy Volunteers-Reference-Cited by-同舟云学术

First‐in‐Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742, a Dual Antagonist of Toll‐like Receptors 7 and 8, in Healthy Volunteers

Published:2022-10-11 Issue:4 Volume:12 Page:363-375
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharm in Drug Dev

Author:

Yamakawa Naoto¹,Tago Fumitoshi¹,Nakai Kenya¹,Kitahara Yasumi²,Ikari Shingo¹,Hojo Seiichiro¹,Hall Nancy²,Aluri Jagadeesh²,Hussein Ziad³,Gevorkyan Hakop⁴,Maruyama Tatsuya⁵,Ishizaka Sally⁶,Yagi Takuya²

Affiliation:

1. Eisai Co., Ltd. Bunkyo‐ku Tokyo Japan

2. Eisai Inc. Nutley New Jersey USA

3. Eisai Ltd. Hatfield UK

4. California Clinical Trials Medical Group in affiliation with PAREXEL, Glendale Glendale California USA

5. Clinical Research Promotion Center The University of Tokyo Hospital Bunkyo‐ku Tokyo Japan

6. Eisai Inc./Eisai Center for Genetics Guided Dementia Discovery Cambridge Massachusetts USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.1176

Reference25 articles.

1. State‐of‐the‐art treatment of systemic lupus erythematosus

2. Toll-like receptor signalling

3. TLR7 gain-of-function genetic variation causes human lupus

4. Toll-Like Receptor Pathways in Autoimmune Diseases

5. Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD11b suppresses TLR7-driven inflammatory signaling to protect against lupus nephritis;2024-07-26

2. B cell activation and autoantibody production in autoimmune diseases;Best Practice & Research Clinical Rheumatology;2024-05

3. Safety, Pharmacokinetics, Biomarker Response, and Efficacy of E6742, a Dual Antagonist of Toll-Like Receptors 7 and 8, in a First-in-Patient, Randomized, Double-Blind, Phase 1/2 Study in Systemic Lupus Erythematosus;2024-04-27

4. Targeting TLR Signaling Cascades in Systemic Lupus Erythematosus and Rheumatoid Arthritis: An Update;Biomedicines;2024-01-09

5. Endosomal Toll-Like Receptors as Therapeutic Targets for Autoimmune Diseases;Advances in Experimental Medicine and Biology;2024